The unlikely hero of Mendel's Dwarf, Benedict (Ben) Lambert, will be familiar to many readers. Many of us have worked with scientists like Ben, have heard them lecture and read their work. But even if you can relate to Ben as a character, Simon Mawer's revelations about the man behind the science will probably come as something of a shock. Ben is obsessed with science, sex, Mendel and Mrs Jean Miller.
Ben Lambert's research group is responsible for showing that FGF3 is mutated in achondroplasia, the most common form of dwarfism. Ben himself is an achondroplastic dwarf (giving news headline writers the opportunity for such gems as: "Dwarf biologist discovers himself"). He is also featured in a television documentary that seeks to show the world, scientific and non-scientific, through Ben's eyes.
Peer recognition follows and he is invited to give a keynote lecture at the Mendel Symposium in Brno. For Ben, this is both a spiritual and family homecoming as he is a greatgreat-great nephew of Mendel. As you might imagine him boasting after a few beers, Ben shares 3% of his genes with a genius. An added bonus in the novel is a synopsis of the Mendel Lecture in which Ben castigates the eugenics trends that often stalk advances in genetics.
Ben is a scientist, Ben is a geneticist, Ben is a dwarf but, ultimately, Ben is a man. Some will find Mawer's book distasteful because of its focus on sex. Men have a Y chromosome which encodes the SRY gene that induces testicular development, and testes produce testosterone. I recall a parents' evening at my son's primary school. One parent demanded that the school 
Gazetteer SmithKline Beecham
What is it famous for? At the moment, failing to merge with Glaxo Wellcome. These two giants of the British pharmaceutical industry recently caused havoc on the stock markets by announcing a hastily formed merger agreement that just as rapidly fell apart. This mother of all mergers would have created the world's third largest company, with a market value of £100 billion, and the biggest drug company by far with 8% of the world market, way ahead of the nearest rivals, Merck and Novartis.
But wasn't SmithKline merging with
AHP? Secret merger talks with AHP (American Home Products) started last November. But no sooner was a deal announced in January than SmithKline got a better offer from Glaxo Wellcome and pulled the plug on AHP.
So is SmithKline an attractive partner?
SmithKline has two drugs that each make more than a billion dollars a year: the anti-depressant Seroxat (the main rival to Prozac) and the antibiotic Augmentin. Other products include an arthritis drug, Relifex, and a successful range of vaccines but much of its revenue in fact comes from an enormous range of consumer brands and over-thecounter remedies. It was expected that merger with Glaxo Wellcome would have meant abandoning some of SmithKline's best-selling drugs to avoid a regulatory enquiry, such as the anti-herpes drug Famvir and the anti-nausea drug Kytril.
What about basic research?
The company opened a state-of-the-art research facility a year ago in Harlow, UK at a cost of £250 million. It has invested heavily in genetic research, especially in gene identification technology, defining hundreds of pharmaceutical development targets. But that's an expensive business. One of the much-touted benefits of the merger with Glaxo Wellcome was the huge Research and Development organization it would have created -with a budget of £1.9 billion, twice that of the nearest rival.
What's it like to work there? Since SmithKline Beecham was created from SmithKline Beckman (US) and the UK's Beecham Group in 1989, it has been far more an American company than anything else. Anyone used to an academic environment might find the prevailing smart dress code and nine-to-five mentality somewhat strange, but it's rumoured that at least the Research and Development Division -of which eccentric former Cambridge Genetics Professor Peter Goodfellow is Vice-President -still manages to retain an unorthodox atmosphere more condusive to research.
Why did the Glaxo Wellcome merger collapse?
The deal is thought to have foundered because of a clash of management egos. Certainly, both SmithKline's Chief Executive Jan Leschly -a go-getting Dane and former world-class tennis playerand Glaxo's Executive Chairman Richard Sykes are powerful personalities. The break-up is particularly embarrassing for SmithKline. As one city fund manager said: "SmithKline has already jilted the bride to run off with the best man. Now they cannot even get it together with the best man."
So is it a case of 'divided we fall'?
There is speculation that SmithKline has made itself a target for an aggressive takeover. The company will certainly have its work cut out to restore its credibility. Both Augmentin and Seroxat face challenges to patent protection and may soon have generic competition. SmithKline needs to prove it can produce major new drugs to replace them. 
